Literature DB >> 562691

Platelet-bound complement (C3) in immune thrombocytopenia.

T W Hauch, W F Rosse.   

Abstract

The fixation of complement to the circulating platelet in immune thrombocytopenia was detected by measurement of one of the complement components, C3, on the surface of platelets from patients with idiopathic thrombocytopenic purpura (ITP) and systemic lupus erythematosus (SLE) using the anti-C3 consumption assay. The surface IgG was determined simultaneously using the previously described anti-IgG consumption assay. Washed platelets from normal controls had 3.5 fg (10(-15) g) of C3, or about 11,000 molecules, per platelet, an amount comparable to the IgG (4.1 FG, or 15,000 molecules, per platelet). For most patients with ITP both C3 and IgG were increased on the platelet surface, although for 5 of 16 patients only IgG was increased. Two patients with SLE and thrombocytopenia had an increase in both C3 and Ig, six patients with SLE who were not thrombocytopenic had normal amounts of membrane-bound C3 and IgG. In 5 patients, 3 with ITP and 2 with collagen vascular disease, both surface immunoproteins decreased with successful treatment of the thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 562691

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  The effect of antiplatelet autoantibodies on megakaryocytopoiesis.

Authors:  Robert McMillan; Diane Nugent
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

2.  In vitro fixation of C3d and C5b-9 on platelets by human platelet reactive antibodies.

Authors:  V Kiefel; A Salama; C Mueller-Eckhardt
Journal:  Blut       Date:  1989-01

3.  Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice.

Authors:  R J Kurlander; J Hall
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

Review 4.  The role of complement in immune clearance of blood cells.

Authors:  U E Nydegger; M D Kazatchkine
Journal:  Springer Semin Immunopathol       Date:  1983

5.  Platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura.

Authors:  J Winiarski; G Holm
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

6.  Platelet antibodies in idiopathic thrombocytopenic purpura.

Authors:  W A Veenhoven; G S Van der Schans; H O Nieweg
Journal:  Clin Exp Immunol       Date:  1980-03       Impact factor: 4.330

7.  Platelet antibodies of the IgM class in immune thrombocytopenic purpura.

Authors:  D B Cines; S B Wilson; A Tomaski; A D Schreiber
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

8.  Activation of human complement by immunoglobulin G antigranulocyte antibody.

Authors:  P K Rustagi; M S Currie; G L Logue
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

9.  Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation.

Authors:  Jennifer Yeung; Benjamin E Tourdot; Pilar Fernandez-Perez; Joanne Vesci; Jin Ren; Christopher J Smyrniotis; Diane K Luci; Ajit Jadhav; Anton Simeonov; David J Maloney; Theodore R Holman; Steven E McKenzie; Michael Holinstat
Journal:  Blood       Date:  2014-08-06       Impact factor: 22.113

Review 10.  Immune Thrombocytopenic Purpura as a Hemorrhagic Versus Thrombotic Disease: An Updated Insight into Pathophysiological Mechanisms.

Authors:  Claudia Cristina Tărniceriu; Loredana Liliana Hurjui; Irina Daniela Florea; Ion Hurjui; Irina Gradinaru; Daniela Maria Tanase; Carmen Delianu; Anca Haisan; Ludmila Lozneanu
Journal:  Medicina (Kaunas)       Date:  2022-02-01       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.